Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

3 U.S. Children with COVID-19 Have Rare Inflammatory Syndrome

Julie Steenhuysen  |  

CHICAGO (Reuters)—Three U.S. children infected with the coronavirus are being treated for a rare inflammatory syndrome that appears similar to one that has raised concerns by doctors in Britain, Italy and Spain, a specialist treating the patients told Reuters. All three—who range in age from 6 months to 8 years—have undergone treatment at Columbia University…

Trial of Gilead’s Potential Coronavirus Treatment Running Ahead of Schedule

Deena Beasley  |  

(Reuters)—A key U.S. government trial of Gilead Sciences Inc.’s experimental coronavirus treatment may yield results as early as mid-May, according to the study’s lead investigator, after doctors clamored to enroll their patients in the study. Preliminary findings from the randomized trial of the antiviral drug remdesivir, begun in February by the National Institute of Allergy…

U.S. Supreme Court Rules for Insurers over $12 billion Obamacare Claims

Lawrence Hurley  |  

WASHINGTON (Reuters)—The U.S. Supreme Court ruled in favor of health insurers seeking $12 billion from the federal government under a program set up by the Obamacare law aimed at encouraging them to offer medical coverage to previously uninsured Americans. The 8–1 ruling authored by liberal Justice Sonia Sotomayor paves the way for a significant one-time…

Sarilumab Trial Data Shows It May Only Help Critical COVID-19 Patients

Saumya Joseph  |  

(Reuters)—On April 27, Regeneron Pharmaceuticals Inc. and Sanofi SA said on Monday that their arthritis drug sarilumab (Kevzara) may only help the sickest patients with COVID-19, dampening hopes that the therapy could potentially reach a larger pool of patients with the disease. The drugmakers said they would test high doses of sarilumab only in critically…

U.S. FDA Warns Against Using Hydroxychloroquine for COVID-19

Reuters Staff  |  

(Reuters)—On April, the U.S. Food and Drug Administration (FDA) cautioned against the use of malaria drug hydroxychloroquine (HCQ) in COVID-19 patients even as President Donald Trump, who has touted it as a “game changer,” advocated for an additional review. The drug, first approved in 1955, provided no benefit and potentially higher risk of death for…

Locum Tenens as a Resource for Practices During the COVID-19 Outbreak

  |  

As the number of COVID-19 cases continues to rise in the U.S., the fast spread of the virus is causing gaps in practice staffing, and patient influx will likely increase, leaving systems needing more providers. The use of locum tenens physicians can help practice fill gaps at your organization caused by COVID-19. Below we offer…

Reimbursement Tips: Telemedicine & Coding in the Time of COVID-19

Kimberly Retzlaff  |  

Humans may fear change as a general rule, but we’re adaptable when we need to be. In this era of COVID-19 and social distancing, medical practices and payers are adapting to an increased use of telemedicine, which enables providers to see their patients without being in a room with them. To cope, the Centers for…